Company Profile

Intabio Inc
Profile last edited on: 5/19/21      CAGE: 7HLY2      UEI: MK59DMGJKYP4

Business Identifier: Precision solutions for biotherapeutic analysis through imaged cIEF-MS
Year Founded
First Award
Latest Award
Program Status
Active (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

9655 Eureka Drive
Newark, CA 94560
   (650) 644-8881
Location: Single
Congr. District: 17
County: Alameda

Public Profile

Intabio Inc had been developing an analytical platform - designated Blaze™ - designed to transform and accelerate the development of biotherapeutic drugs by enabling early product quality characterization and producing profound efficiency gains across all stages of biopharmaceutical development and manufacturing. The Blaze system enables direct coupling of imaged cIEF charge variant analysis with high-resolution mass spectrometry to detect intact proteins, offering a many-fold higher throughput over traditional methods. This feature has ben judged likely to enable biopharma companies to meet the accelerated timelines required for breakthrough therapy applications, reducing the risk of costly production delays and failures - potentially improving product quality, reducing manufacturing cost, and increasing speed to market, Intabio's first product, the Blaze system, is a microchip-based instrument system that will provide rapid detection and identification of subtle protein modifications - modifications that can undermine the stability and efficacy of biotherapeutic drugs such as monoclonal antibodies and recombinant proteins.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2019 2 NIH $2,321,326
Project Title: Commercial Development of a Novel Microfluidic Platform for Real-Time Biopharmaceutical Analysis
2018 1 NSF $224,996
Project Title: Development of a Rapid Biologics Characterization Device

Key People / Management

  Lena Wu -- CEO

  Erik T Gentalen -- CTO